AN OPEN-LABEL, DOSE-ESCALATION, DOSE-FINDING, AND PROOF-OF-CONCEPT TRIAL OF SP-420 IN SUBJECTS WITH TRANSFUSION-DEPENDENT ALPHA- OR BETA-THALASSEMIA OR LOW-RISK MYELODYSPLASTIC SYNDROMES
- Registry ID
- P-SP420-THAL-01
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Study type
- INTERVENTIONAL
- Sponsor
- PHARMACOSMOS A/S
- Start date
- 2023-10-16
- Last update
- 2022-11-07
Conditions
- THALASSEMIA
- MYELODYSPLASTIC SYNDROME
Related clinical trials
- A PHASE 1 STUDY OF TAK-243 FOR RELAPSED OR REFRACTORY ACUTE MYELOID
LEUKEMIA OR MYELODYSPLASTIC SYNDROMES WITH INCREASED BLASTS
- A PHASE 2, RANDOMIZED, OPEN-LABEL, STUDY OF MOMELOTINIB IN PARTICIPANTS WITH
ANEMIA DUE TO LOW-RISK MYELODYSPLASTIC SYNDROME
- A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ELRITERCEPT (KER-050) FOR THE TREATMENT OF TRANSFUSION-DEPENDENT ANEMIA IN ADULT PARTICIPANTS WITH VERY LOW-, LOW-, OR INTERMEDIATE-RISK MYELODYSPLASTIC SYNDROMES (MDS) (RENEW)
- EVALUATION OF SUPPORTIVE CARE TREATMENTS AMONG OUTPATIENTS WITH MYELODYSPLASTIC SYNDROME AND ACUTE MYELOID LEUKEMIA: A MULTICENTER PILOT TRIAL (MYELO-CAN)
- PROTOCOL 10538, VENETOCLAX IN COMBINATION WITH ASTX727, AN ALL-ORAL THERAPY FOR CHRONIC MYELOMONOCYTIC LEUKEMIA AND OTHER MDS/MPN WITH EXCESS BLASTS (VICTORY-MDS/MPN): A RANDOMIZED, PHASE 2 TRIAL
- A PHASE 2 OPEN-LABEL STUDY TO EVALUATE ETAVOPIVAT FOR THE TREATMENT OF ANEMIA IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS)
View on source registry